In 2018, the US military launched a program to use its superhumans to diagnose and treat diseases.
Now, the government is looking to use the same capabilities to develop AI, and researchers have already begun to test the potential for using superhumans in medicine.
The Future of Medicine project aims to use artificial intelligence to better understand diseases, including cancers and other complex conditions.
The team of researchers at Carnegie Mellon University, Carnegie Mellon National Robotics Lab, and Carnegie Mellon Health Sciences Center has created a machine learning tool that will eventually be used to diagnose, treat, and eventually cure diseases.
The AI tool is called MIRACLE and is the brainchild of Dr. Andrew Ng, who also co-founded AI company Neuralink.
The program is also a joint effort between the US Army, the National Institutes of Health, the American Cancer Society, and the National Science Foundation.
The Army and NIH have already signed a $100 million contract to fund MIRACE.
The tool, which was recently released to the public, uses a computer model to predict a disease based on the patient’s symptoms, their medical history, and medical history and family history.
The model then uses the data to develop an algorithm that uses a combination of the data and human judgment to identify a promising biomarker.
The goal is to use machine learning to identify biomarkers that could be useful in the development of a novel cancer drug.
If all goes according to plan, the program could one day lead to a treatment that’s safer and more effective than existing treatments.
“We want to be able to make a drug that can treat a disease that could potentially be fatal without any side effects,” Ng told the Associated Press.
“It’s an incredibly ambitious goal, and it’s a big challenge.
But it’s also an opportunity to really explore these fields, to really look at what are the big problems in medicine, and where do we go from there?”
The research is being funded by the National Institute of Allergy and Infectious Diseases, the Office of Science of the National Cancer Institute, and National Science Council.
The project is being overseen by a team of 25 researchers from Carnegie Mellon, the University of Texas, and New York University.
For more, check out the AP story below.
